FANCA and cancer: While further work is required to elucidate a mechanism of action, it is proposed to bind the FANCL RING domain, preventing interaction with the E2 ligase [81].This development represents an exciting starting point for specific FA targeting inhibitors which may be further adapted to improve potency, and could lead to a new class of mechanistically characterised inhibitors which can be more easily translated to the clinic for treatment of chemoresistant cancers than current broad spectrum inhibitors.